Sanara MedTech ( (SMTI) ) has released its Q2 earnings. Here is a breakdown of the information Sanara MedTech presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanara MedTech Inc. is a medical technology company that develops and commercializes innovative products aimed at improving clinical outcomes and reducing healthcare costs in the surgical, chronic wound, and skin markets. The company operates primarily in North America, focusing on advanced wound care and surgical tissue repair markets.
In its second quarter of 2025, Sanara MedTech reported a 28% increase in net revenue year-over-year, reaching $25.8 million. The company also announced a strategic review process for its Tissue Health Plus subsidiary, aiming to maximize shareholder value.
Key financial highlights include a reduction in net loss to $2.0 million from $3.5 million in the previous year, and a significant increase in adjusted EBITDA to $2.7 million from $0.6 million. The Sanara Surgical segment showed strong performance, generating a net income of $0.5 million and a segment adjusted EBITDA of $4.7 million, while the THP segment faced challenges with a net loss of $2.5 million.
Looking ahead, Sanara MedTech’s management remains optimistic about the growth potential of its Sanara Surgical segment, driven by the expansion of its distribution network and increased penetration in healthcare facilities. The company is also exploring strategic alternatives for its THP segment to enhance shareholder value.